RT Journal Article
SR Electronic
T1 SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Šibenik-Knin County, Croatia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20095158
DO 10.1101/2020.05.11.20095158
A1 Ivan Jerković
A1 Toni Ljubić
A1 Željana Bašić
A1 Ivana Kružić
A1 Nenad Kunac
A1 Joško Bezić
A1 Arijana Vuko
A1 Alemka Markotić
A1 Šimun Anđelinović
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20095158.abstract
AB BACKGROUND As a result of global spread, COVID-19 has also affected the Republic of Croatia in the last week of February. Although official data show that the number of newly infected is declining, it is still unknown what proportion of the population has been affected by the disease.AIM To examine seroprevalence of SARS-CoV-2 antibodies in industry workers population sample.METHODS From 23 to 28 April 2020, we conducted serological testing for antibodies (IgG and IgM) on 1494 factory employees living in the Split-Dalmatia and Šibenik-Knin County (Croatia). We analysed antibody seroprevalence on the level of the company, county, and separately for employees living at the factory premises with limited mobility during the lockdown measures.RESULTS In a total sample of tested company employees, we detected antibodies in 1.27% of participants (95% CI 0.77-1.98%). In Split facility 13/1316 (0.99%, 95% CI 0.53-1.68%) of participants were tested positive, of which 13/1079 (1.20%, 95% CI 0.64-2.05%) of those living outside the facility and 0/237 (0%, 95% CI 0-1.26%) of those living inside the facility. In Knin facility, 6/178 (3.37%, 95% CI 1.25-7.19%) participants were tested positive for antibodies. The difference between Split (no mobility restrictions) and Knin, was not statistically significant (χ2 = 3.47, P = 0.062).CONCLUSIONS The study showed relatively small SARS-CoV-2 antibody seroprevalence in the DIV Group population sample. When the study findings are interpreted on the county levels, they could indicate that most of the counties’ population was not exposed to the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe tests used in this study were purchased by the DIV Group.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [ŽB], upon reasonable request.